Group 1 - The CRO concept index rose by 2.56%, ranking 10th among concept sectors, with 64 stocks increasing in value, led by Hanyu Pharmaceutical, Boteng Co., and Meidi Xi, which rose by 7.87%, 6.85%, and 6.28% respectively [1][2] - The top three stocks in terms of net inflow of main funds were Hanyu Pharmaceutical with a net inflow of 172 million yuan, followed by Fosun Pharma and Huace Testing with net inflows of 40.96 million yuan and 36.48 million yuan respectively [2][3] Group 2 - The main fund inflow rates for stocks such as Ruizhi Pharmaceutical, Hanyu Pharmaceutical, and Jiannang Technology were 10.21%, 10.19%, and 8.41% respectively, indicating strong investor interest [3] - The CRO concept sector saw a net inflow of 322 million yuan today, with 45 stocks experiencing net inflows, and five stocks exceeding 30 million yuan in net inflow [2][3] Group 3 - The stocks with the highest trading turnover in the CRO concept included Hanyu Pharmaceutical with a turnover rate of 10.59%, followed by Fosun Pharma at 0.88% and Huace Testing at 5.74% [3][4] - The overall performance of the CRO concept was positive, with several stocks showing significant gains, while a few, such as Inno Laser and ST Weiming, experienced declines of 3.16% and 1.74% respectively [1][5]

Core Viewpoint - The company is currently operating normally but reported a loss for the first half of the year, with further details available in the official announcement [1] Group 1: Financial Performance - The company continues to experience losses in its semi-annual performance, with specifics to be detailed in the upcoming regular reports [1] - There is no risk of being classified as ST (Special Treatment) under the Shenzhen Stock Exchange's GEM listing rules [1] Group 2: Future Plans - The company is committed to advancing the market launch and sales of its injectable Epinavirin to increase market share [1] - There is a focus on expanding the pipeline for innovative drug development, with plans to increase investment in this area to prepare for future growth [1]

证券代码：300683 证券简称：海特生物 公告编号：2025-040 鉴于冉明东先生的辞职将导致公司独立董事人数少于董事会成员的三分之 一，为保证公司董事会的正常运行，根据《上市公司独立董事管理办法》《公司 章程》《独立董事工作制度》及《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》的相关规定，其离职将在公司股东大会选举产 生新任独立董事之日起生效。在此之前，冉明东先生仍按照相关法律法规和《公 司章程》的规定继续履行独立董事及董事会下属委员会的相关职责，公司将按照 法定程序尽快完成独立董事补选工作。 截至本公告披露日，冉明东先生未持有公司股份，不存在应当履行而未履行 的承诺事项。冉明东先生在任职期间勤勉尽责、恪尽职守，公司董事会对冉明东 先生在任期间为公司发展所做出的贡献表示衷心的感谢！ 特此公告。 武汉海特生物制药股份有限公司 关于独立董事离职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，无虚假记 载、误导性陈述或重大遗漏。 武汉海特生物制药股份有限公司（以下简称"公司"）董事会于近日收到独 立董事冉明东先生的书面辞职报告，冉明东先生因个人原因，申请辞去公司第 ...

Core Points - As of September 19, the number of shareholders for Hite Bio (300683) is reported to be 15,886 [1]

证券日报网讯海特生物（300683）9月11日在互动平台回答投资者提问时表示，截至9月10日公司股东人 数为15530户。 ...

Company Overview - Hite Bio is located in Wuhan Economic and Technological Development Zone, established on April 8, 1992, and listed on August 8, 2017. The company focuses on the research, production, and sales of innovative biopharmaceuticals, as well as providing small molecule chemical pharmaceutical research and contract drug manufacturing services [1][2]. Financial Performance - For the first half of 2025, Hite Bio reported revenue of 275 million yuan, a year-on-year decrease of 3.36%. The net profit attributable to the parent company was -39.18 million yuan, reflecting a significant year-on-year decline of 72.10% [2]. - The company has distributed a total of 85.23 million yuan in dividends since its A-share listing, with 17.02 million yuan distributed over the past three years [3]. Stock Performance - As of September 9, Hite Bio's stock price was 40.83 yuan per share, with a market capitalization of 5.344 billion yuan. The stock has increased by 72.21% year-to-date but has seen a decline of 9.31% over the last five trading days and 19.12% over the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on July 23 [1]. Shareholder Information - As of August 29, Hite Bio had 14,600 shareholders, an increase of 8.86% from the previous period. The average number of tradable shares per shareholder was 8,349, which decreased by 8.14% [2]. Business Segments - The main revenue sources for Hite Bio include technical service income (57.20%), injectable mouse nerve growth factor (25.59%), and injectable Epoetin (17.04%), with other income contributing 0.17% [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, and is involved in various concept sectors such as traditional Chinese medicine, raw materials, small-cap stocks, mergers and acquisitions, and the Hubei Free Trade Zone [2].

国投证券股份有限公司关于 武汉海特生物制药股份有限公司持续督导工作 2025 年半年度定期现场检查报告 2、查阅大额资金往来的交易合同等资料； 1 | 2、是否在股票上市后 个月内建立内部审计制度并设立内 6 | | √ | | --- | --- | --- | | 部审计部门（如适用） | | | | 3、内部审计部门和审计委员会的人员构成是否合规（如适 | √ | | | 用） | | | | 4、审计委员会是否至少每季度召开一次会议，审议内部审 | √ | | | 计部门提交的工作计划和报告等（如适用） | | | | 5、审计委员会是否至少每季度向董事会报告一次内部审计 | √ | | | 工作进度、质量及发现的重大问题等（如适用） | | | | 6、内部审计部门是否至少每季度向审计委员会报告一次内 | | | | 部审计工作计划的执行情况以及内部审计工作中发现的问 | √ | | | 题等（如适用） | | | | 7、内部审计部门是否至少每季度对募集资金的存放与使用 | √ | | | 情况进行一次审计（如适用） | | | | 8、内部审计部门是否在每个会计年度结束前二个月内向审 | √ | ...

2025年半年度持续督导跟踪报告 国投证券股份有限公司 关于武汉海特生物制药股份有限公司 | 保荐机构名称：国投证券股份有限公司 | 被保荐公司简称：海特生物 | | --- | --- | | 保荐代表人姓名：孙素淑 | 联系电话：021-55518389 | | 保荐代表人姓名：燕云 | 联系电话：021-35082978 | 一、保荐工作概述 2 | 1.信息披露 | 无 | 不适用 | | --- | --- | --- | | 2.公司内部制度的建立和 | 无 | 不适用 | | 执行 | | | | 3．"三会"运作 | 无 | 不适用 | | 4.控股股东及实际控制人 | 无 | 不适用 | | 变动 | | | | 5.募集资金存放及使用 | 无 | 不适用 | | 6.关联交易 | 无 | 不适用 | | 7.对外担保 | 无 | 不适用 | | 8.收购、出售资产 | 无 | 不适用 | | 9.其他业务类别重要事项 | | | | （包括对外投资、风险投 | 无 | 不适用 | | 资、委托理财、财务资助、 | | | | 套期保值等） | | | | 10．发行人或者其聘请的中 | | ...

Market Overview - The Shanghai Composite Index closed at 3875.53 points, with a change of 0.46% [1] - The total trading volume of A-shares reached 27,776.47 billion yuan [1] Technical Analysis - A total of 63 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA at 50.56 yuan, 10-day MA at 51.97 yuan, a difference of -2.72% [1] - Titan Technology: 5-day MA at 27.25 yuan, 10-day MA at 27.85 yuan, a difference of -2.16% [1] - Anglikang: 5-day MA at 50.17 yuan, 10-day MA at 51.27 yuan, a difference of -2.15% [1] Individual Stock Performance - Haitai Biological: Today's change of -2.67%, with a turnover rate of 8.82% [1] - Titan Technology: Today's change of -2.29%, with a turnover rate of 4.22% [1] - Anglikang: Today's change of -0.85%, with a turnover rate of 6.98% [1] - Other stocks with notable performance include: - Rainbow Group: Today's change of -0.13%, with a turnover rate of 3.47% [1] - Wanli Stone: Today's change of -0.51%, with a turnover rate of 2.18% [1] Additional Observations - The market shows a trend of declining stock prices for several companies, indicating potential bearish sentiment [1][2] - The analysis of moving averages suggests a cautious approach for investors focusing on these stocks [1][2]

Market Overview - The Shanghai Composite Index is at 3864.71 points with a change of 0.18% [1] - The total trading volume of A-shares is 138.21 billion yuan [1] Technical Analysis - 62 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA is -2.28% below the 10-day MA [1] - Titan Technology: 5-day MA is -2.07% below the 10-day MA [1] - Anglikang: 5-day MA is -1.88% below the 10-day MA [1] Individual Stock Performance - Haitai Biological (300683): Today's change is +1.95%, with a 5-day MA of 51.01 yuan and a 10-day MA of 52.20 yuan [1] - Titan Technology (688133): Today's change is -1.41%, with a 5-day MA of 27.30 yuan and a 10-day MA of 27.88 yuan [1] - Anglikang (002940): Today's change is +1.84%, with a 5-day MA of 50.44 yuan and a 10-day MA of 51.40 yuan [1] - Other stocks with notable performance include: - Rainbow Group (300314): +0.04% change, 5-day MA of 23.44 yuan [1] - Wanli Stone (002785): -0.89% change, 5-day MA of 29.62 yuan [1] Summary of Stocks with Death Cross - A list of stocks experiencing a death cross includes: - Haitai Biological, Titan Technology, Anglikang, and others with varying degrees of percentage differences between their moving averages [1][2]